A Multicenter, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines
Phase: PHASE2
Conditions: Glabellar Frown Lines
Sponsor: Galderma R&D

A Multicenter, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate 
the Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe 
Glabellar Lines 
NCT Number: NCT03736928 
Protocol Document Date: 10Aug2018